Label status: In January 2025, the Ozempic label was updated to state that it is not recommended in patients with severe gastroparesis, but does not indicate that the drug itself may cause the condition
Combined with baseline biomarkers (fasting insulin, glucose control, inflammatory status), genetic insights can support a more personalized framework for setting realistic treatment goals
Yes, it may be for many women, especially those who experience sudden changes in weight or metabolic changes
Phase 3 TRIUMPH Program (Ongoing) First successful readout: TRIUMPH-4 (obesity/overweight + knee osteoarthritis, no diabetes
The devolved nations assess medications separately
Werner, U., Haschke, G., Herling, A